Lippes Mathias partner Tod Melgar discusses recent federal rulings that limit medical practitioners' immunity from patent liability, especially in regenerative stem cell treatments. The article examines how these decisions heighten risks for healthcare providers using patented technologies in innovative procedures. Melgar highlights the challenges facing medical practitioners under evolving patent law interpretations.